News | May 28, 2015

CVRx Barostim Therapy Clinical Trial Results Presented at ESC-Heart Failure Conference

One hundred forty-six patient trial finds Barostim device safe and effective at improving quality of life for heart failure patients

CVRx, Barostim therapy, heart failure, trial, ESC-Heart Failure, Muller-Ehmsen

May 28, 2015 — CVRx Inc. announced that positive results from the 'Barostim Therapy for Heart Failure' randomized, controlled clinical trial were presented at the ESC-Heart Failure 2015 Annual Conference in a late-breaking trial session. Results were presented by Prof. Jochen Müller-Ehmsen, M.D., Ph.D., from Asklepios Hospital Altona in Hamburg, Germany.

Safety and efficacy results with Barostim therapy comparing patients not previously treated with cardiac resynchronization therapy to patients who continued to suffer from advanced heart failure despite prior treatment with CRT were presented. At six months in the no-CRT group, Müller-Ehmsen reported that quality of life scores improved significantly, six-minute hall walk distance and left ventricular ejection fraction increased significantly, and heart failure hospitalization days were significantly reduced in Barostim therapy patients compared to controls.  

"Based on our own experience with Barostim therapy and the safety and efficacy data now published, we are very confident to offer this therapy to our heart failure patients who are still symptomatic despite receiving optimal heart failure therapy", Müller-Ehmsen said.

"Based on results of this trial we have had the good fortune of presenting the data at three late-breaking clinical trial sessions and generating two simultaneous publications over the last three months. This is unprecedented", said William Abraham, M.D., from The Ohio State University, who served on the trial's steering committee.

CVRx completed a 146-patient randomized, controlled clinical trial to determine the performance of Barostim therapy for patients suffering from chronic heart failure with advanced symptoms. Aggregate results were recently presented at the American College of Cardiology's (ACC) annual scientific session and simultaneously published in the Journal of the American College of Cardiology: Heart Failure. Barostim therapy was shown to be safe and significantly improved patient functional and exercise capability, as well as quality of life, when compared to optimal medical therapy. Barostim therapy also significantly reduced the plasma biomarkers of heart failure severity and the burden of heart failure hospitalizations in patients with heart failure.

Barostim neo is a second-generation device that uses CVRx-patented technology designed to trigger the body's own natural blood flow regulation system to treat patients suffering from chronic heart failure. The therapy is also a treatment option for patients with resistant hypertension. The system electrically activates the baroreflex, the body's natural mechanism to regulate cardiovascular function. By activating this afferent pathway, Barostim therapy reduces sympathetic activity and increases parasympathetic activity, ultimately restoring sympatho-vagal balance.

Key benefits include:

  • The Barostim neo can be turned on and off to demonstrate acute results;
  • It can be adjusted to meet each patient's individual therapy needs;
  • It is a reversible treatment, meaning the therapy can be turned off;
  • It provides 100 percent adherence to treatment by continuously activating the baroreflex;
  • It is compatible with and complementary to implantable cardiac rhythm management devices; and 
  • It is now magnetic resonance (MR)-conditional, or safe for use under specified condition in Europe.

 

For more information: www.cvrx.com

Related Content

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

News | Cardiovascular Clinical Studies | July 22, 2020
July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to re
The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp